Table 2.
Baseline demographic, clinical, and biochemical characteristics of CRIC Study participants without HF at baseline by quintile of NT-proBNP
| Characterisitics | NT-proBNP Quintile (n), pg/mla | P Value | ||||
|---|---|---|---|---|---|---|
| ≤47.6 (n=697) | >47.6–95.8 (n=697) | >95.8–188.8 (n=696) | >188.8–433.0 (n=697) | >433.0 (n=696) | ||
| Age, yr | 52.9 (11.7) | 57.2 (10.8) | 58.9 (11.2) | 59.9 (10.5) | 60.5 (10.0) | <0.001 |
| Women | 232 (33.3%) | 330 (47.3%) | 338 (48.6%) | 370 (53.1%) | 317 (45.5%) | <0.001 |
| Race/ethnicity | <0.001 | |||||
| Non-Hispanic white | 300 (43.0%) | 306 (43.9%) | 325 (46.7%) | 309 (44.3%) | 252 (36.2%) | |
| Non-Hispanic black | 317 (45.5%) | 295 (42.3%) | 264 (37.9%) | 254 (36.4%) | 263 (37.8%) | |
| Hispanic | 45 (6.5%) | 62 (8.9%) | 88 (12.6%) | 103 (14.8%) | 157 (22.6%) | |
| Other | 35 (5.0%) | 34 (4.9%) | 19 (2.7%) | 31 (4.4%) | 24 (3.4%) | |
| eGFR, ml/min per 1.73 m2b | 58.1 (16.8) | 49.7 (16.4) | 45.2 (15.3) | 40.6 (13.8) | 35.0 (12.4) | <0.001 |
| 24-hour urine protein, g/d | 0.1 (0.06–0.3) | 0.1 (0.07–0.6) | 0.2 (0.07–0.7) | 0.2 (0.08–1.1) | 0.7 (0.1–2.8) | <0.001 |
| Diabetes | 218 (31.3%) | 291 (41.8%) | 315 (45.3%) | 362 (51.9%) | 429 (61.6%) | <0.001 |
| History of MI/stroke/PAD | 79 (11.3%) | 121 (17.4%) | 172 (24.7%) | 215 (30.8%) | 323 (46.4%) | <0.001 |
| Current smoker | 66 (9.5%) | 76 (10.9%) | 83 (11.9%) | 99 (14.2%) | 124 (17.8%) | <0.001 |
| Alcohol use | 511 (73.3%) | 496 (71.2%) | 433 (62.2%) | 419 (60.1%) | 371 (53.3%) | <0.001 |
| Body mass index, kg/m2 | 31.8 (6.6) | 32.0 (7.5) | 32.1 (8.4) | 32.0 (8.3) | 31.6 (7.7) | 0.76 |
| Systolic BP, mmHg | 118.9 (15.2) | 124.0 (18.5) | 125.0 (18.7) | 131.8 (22.0) | 142.5 (26.1) | <0.001 |
| Diastolic BP, mmHg | 73.0 (11.1) | 72.4 (11.4) | 70.1 (11.8) | 71.3 (13.2) | 72.7 (14.9) | <0.001 |
| Hemoglobin, g/dl | 13.6 (1.6) | 12.9 (1.5) | 12.6 (1.6) | 12.3 (1.7) | 11.8 (1.9) | <0.001 |
| LDL cholesterol, mg/dl | 107.7 (34.0) | 104.5 (35.0) | 104.0 (35.5) | 101.8 (34.1) | 101.2 (37.8) | 0.005 |
| HDL cholesterol, mg/dl | 47.1 (14.2) | 48.2 (15.3) | 49.0 (15.8) | 48.8 (16.8) | 46.7 (15.7) | 0.02 |
| ACE/ARB use | 457 (66.2%) | 467 (67.6%) | 479 (69.1%) | 481 (69.5%) | 458 (66.3%) | 0.56 |
| Diuretic use | 292 (42.3%) | 369 (53.4%) | 404 (58.3%) | 401 (57.9%) | 482 (69.8%) | <0.001 |
| β-Blocker use | 157 (22.8%) | 242 (35.0%) | 305 (44.0%) | 405 (58.5%) | 482 (69.8%) | <0.001 |
| FGF23, RU/ml | 99.6 (73.4–144.8) | 122.7 (86.2–183.7) | 133.2 (94.6–206.0) | 159.3 (107.4–244.5) | 209.1 (136.2–344.0) | <0.001 |
| Serum phosphorus, mg/dl | 3.5 (0.6) | 3.6 (0.6) | 3.7 (0.7) | 3.8 (0.7) | 3.9 (0.7) | <0.001 |
| Total PTH, pg/ml | 41.0 (29.4–56.0) | 47.8 (32.6–77.3) | 51.5 (32.0–78.6) | 57.0 (37.0–94.0) | 74.0 (46.0–123.4) | <0.001 |
| EF from echocardiogramc | 55.6 (6.4) | 56.1 (6.1) | 55.6 (7.0) | 54.8 (7.7) | 52.2 (9.5) | <0.001 |
| LVMI, g/m2.7c | 45.3 (10.4) | 48.6 (11.4) | 49.9 (12.3) | 52.4 (13.2) | 59.7 (15.4) | <0.001 |
MI, myocardial infarction; PAD, peripheral arterial disease; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; RU, relative units.
a
NT-proBNP categories were defined by quintiles.
b
eGFR calculated using serum creatinine and cystatin C (47).
c
From the year 1 clinic visit.